APOE4和CRISPR正在重新定义阿尔茨海默症风险
APOE4 and CRISPR are reframing Alzheimer’s Risk
生物技术与制药领域的最新动态
APOE4 and CRISPR are reframing Alzheimer’s Risk
Eli Lilly becomes first drugmaker to hit $1 trillion in market value
FDA tests new program to speed drugmaker talks; Bezos-linked AI startup raises $106M
GSK, Anaptysbio sue each other over Jemperli revenue
A brain biotech’s top drug fails against MS
Moderna secures $1.5B lifeline as it looks to break even in 2028
Roche pill notches win in early breast cancer - BioPharma Dive
Roche’s MS tablet scores in late-stage studies - BioPharma Dive
Roche taps an AI specialist to craft new brain drugs - BioPharma Dive
Roche dives into MASH with $2.4B deal for 89bio - BioPharma Dive
Illumina to buy SomaLogic in deal worth up to $425M - BioPharma Dive
Roche, answering tariff threat, pledges $50B to US drug production - BioPharma Dive